Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Hepatology International
Literature
1.
2.
Nash E, Sabih AH, Chetwood J, Wood G, Pandya K, Yip T, et al. Drug-induced liver injury in Australia, 2009–2020: the increasing proportion of non-paracetamol cases linked with herbal and dietary supplements. Med J Aust 2021;215:261–268CrossRefPubMed
3.
European Association for the Study of the Liver. EASL clinical practice guidelines: drug-induced liver injury. J Hepatol 2019;70:1222–1261CrossRef
4.
5.
Binns CW, Lee MK, Lee AH. Problems and prospects: public health regulation of dietary supplements. Annu Rev Public Health 2018;39:403–420CrossRefPubMed
Metadata
Title
Drug-induced liver injury from herbal and dietary supplements: a problem in the East and West alike
Authors
Emily Nash
John Chetwood
Simone I. Strasser
Ken Liu
Publication date
01-04-2022
Publisher
Springer India
Keyword
Paracetamol
Published in
Hepatology International / Issue 2/2022
Print ISSN: 1936-0533
Electronic ISSN: 1936-0541
DOI
https://doi.org/10.1007/s12072-021-10289-1

Other articles of this Issue 2/2022

Hepatology International 2/2022 Go to the issue

Original Article

Image-matching digital macro-slide—a novel pathological examination method for microvascular invasion detection in hepatocellular carcinoma

Original Article

Distinctive clinical and genetic features of lean vs overweight fatty liver disease using the UK Biobank

Original Article

Sequential HBV treatment with tenofovir alafenamide for patients with chronic hepatitis B: week 96 results from a real-world, multicenter cohort study

Correction

Correction to: Consensus on the secondary prevention of primary liver cancer

Review Article

Non-alcoholic fatty liver disease association with structural heart, systolic and diastolic dysfunction: a meta-analysis

Original Article

Gender differences in the association of body composition and biopsy-proved nonalcoholic steatohepatitis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits